Št. zadetkov: 17
Pregledni znanstveni članek
Oznake:
brain vulnerability;cognitive decline;molecular biomarkers;neuroimaging;type 2 diabetes;
Type 2 diabetes mellitus (T2DM) is associated with heterogeneous cognitive and functional trajectories rather than a single diabetes-specific encephalopathy. This structured narrative review proposes a conceptual, hypothesis-generating exposure-injury-structure-function framework linking metabolic, ...
Leto:
2026
Vir:
Digitalni repozitorij raziskovalnih organizacij Slovenije
Izvirni znanstveni članek
Oznake:
abdominal cancer;nutritional status;body composition;
Background. The significance of nutritional care in the management of cancer, particularly in the surgical treatment of abdominal cancer, is increasingly acknowledged. Body composition analysis, such as the Bioelectric impedance assay (BIA), and functional tests, e.g., handgrip strength, are used wh ...
Leto:
2023
Vir:
Onkološki inštitut Ljubljana (OI)
Pregledni znanstveni članek
Oznake:
diabetes mellitus;erectile dysfunction;genetic polymorphisms;
Introduction Erectile dysfunction (ED) is a highly prevalent complication of diabetes mellitus (DM), significantly impairing quality of life and psychosocial well-being. The prevalence of ED is estimated to be over 3.5 times higher in men with diabetes mellitus compared to those without. The aetiolo ...
Leto:
2025
Vir:
Medicinska fakulteta (UL MF)
Izvirni znanstveni članek
Oznake:
polymorphism;type 2 diabetes;treatment response;
We investigated the impact of genetic polymorphisms in the GLP1R and SLC5A2 genes on the response to treatment with glucagon-like peptide-1 receptor (GLP-1R) agonists and sodium-glucose co-transporter-2 (SLGT2) inhibitors in patients with type 2 diabetes mellitus (T2DM) in everyday clinical practice ...
Leto:
2025
Vir:
Repozitorij Univerze v Ljubljani (RUL)
Izvirni znanstveni članek
Oznake:
PDE5 inhibitors;pharmacogenetics;folate metabolism;MTHFR;MTR;endothelial dysfunction;single-nucleotide polymorphism;
Background/Objectives: Erectile dysfunction (ED) is a common complication of diabetes mellitus (DM), largely driven by endothelial dysfunction and impaired nitric oxide signaling. Although phosphodiesterase type 5 inhibitors (PDE5i) such as tadalafil are effective, treatment response varies consider ...
Leto:
2026
Vir:
Medicinska fakulteta (UL MF)
Pregledni znanstveni članek
Oznake:
SGLT2 inhibitorji;kardiovaskularna varnost;nefrologija;genetski polimorfizem;
SGLT2 (sodium-glucose cotransporter 2) inhibitors are a new class of antihyperglycaemic drugs that act on the proximal tubules of the kidney. They have shown efficacy in the management of diabetes mellitus type 2 and their cardiovascular and renal safety have been extensively investigated and confir ...
Leto:
2021
Vir:
Medicinska fakulteta (UL MF)
Pregledni znanstveni članek
Oznake:
akutna ishemija;arterijski embolizem;etiologija;diagnostični pristop;
Superior mesenteric artery embolisation is the most common cause of acute mesenteric ischaemia. Superior mesenteric artery embolisation can be caused by various cardiac diseases (myocardial ischaemia or infarction, atrial tachyarrhythmias, endocarditis, cardiomyopathies, ventricular aneurysms and va ...
Leto:
2021
Vir:
Medicinska fakulteta (UL MF)
Pregledni znanstveni članek
Oznake:
debelost;sladkorna bolezen tipa 2;genetski polimorfizem;farmakogenetika;inkretini;
Razvoj sladkorne bolezni tipa 2 je etiopatogenetsko povezan z okoljskimi dejavniki, poleg tega pa je močno genetsko pogojen. Bolnike s sladkorno boleznijo tipa 2 zdravimo z nefarmakološkimi in farmakološkimi ukrepi, pri čemer so se v zadnjih desetletjih v klinični rabi pojavile nove skupine antihipe ...
Leto:
2025
Vir:
Repozitorij Univerze v Ljubljani (RUL)
Pregledni znanstveni članek
Oznake:
genetika;debelost;patogeneza;terapije;CRISPR/Cas9;dual therapy;energy homeostasis;gene therapy;gut–brain axis;microbiota;personalized medicine;
ǂThe ǂgenetic blueprint of obesity
Leto:
2025
Vir:
Repozitorij Univerze v Ljubljani (RUL)
Pregledni znanstveni članek
Oznake:
diabetes mellitus tipa 2;debelost;agonisti receptorjev GLP-1;type 2 diabetes mellitus;obesity;GLP‐1 receptor agonists;
Glucagon-like peptide-1 (GLP-1) receptor agonists are a new class of antihyperglycemic drugs that enhance appropriate pancreatic β-cell secretion, pancreatic α-cell (glucagon) suppression, decrease liver glucose production, increase satiety through their action on the central nervous system, slow ga ...
Leto:
2022
Vir:
Medicinska fakulteta (UL MF)